Skip to main content

Table 4 Multivariable model of variables associated with adherence to endocrine therapy among women who were eligible for Oncotype Dx testing (N = 3949)

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

  OR (95% CI) P
Tested    .09
 Yes 0.88 (0.76–1.02)  
 No (ref)    
Year diagnosed    0.003
 2006–2007 (ref)    
 2008–2009 0.81 (0.70–0.94)  
 2010 0.74 (0.60–0.90)  
Age at diagnosis, years    0.047
 24–39 1.50 (1.12–2.01)  
 40–49 1.05 (0.88–1.25)  
 50–59 (ref)    
 60–63 1.00 (0.83–1.20)  
Race-ethnicity    0.06
 NH white (ref)    
 NH black 1.43 (1.01–2.03)  
 Hispanic 1.04 (0.74–1.45)  
 Other 0.80 (0.61–1.04)  
Marital status    0.003
 Married (ref)    
 Not married 1.24 (1.07–1.44)  
Prior cancer    0.30
 No (ref)    
 Yes 0.85 (0.62–1.16)  
State    0.17
 CA (ref)    
 GA 1.08 (0.85–1.39)  
 KY 0.91 (0.69–1.21)  
 NY 0.82 (0.64–1.05)  
 OH 0.91 (0.71–1.18)  
Area    0.29
 Rural (ref)    
 Urban 0.85 (0.62–1.15)  
Median household income    0.20
 1 (lowest (ref))    
 2 0.98 (0.79–1.22)  
 3 1.11 (0.90–1.37)  
 4 0.98 (0.78–1.23)  
 5 (highest) 0.86 (0.67–1.09)  
Stage    0.75
 I (ref)    
 II 0.97 (0.79–1.18)  
Nodal involvement    0.68
 N0 1.07 (0.80–1.43)  
 N1mic 1.11 (0.88–1.40)  
 N1 (ref)    
HER2 status    0.49
 Negative 1.03 (0.84–1.27)  
 Borderline 1.45 (0.79–2.66)  
 Unknown (ref)    
Hormone receptor status    0.96
 ER and PR both positive (ref)    
 Only ER or PR positive 0.99 (0.82–1.21)  
Histological grade    0.22
 1–2 (well/moderately differentiated) (ref)    
 3 (poorly or not differentiated) 1.11 (0.94–1.31)  
One-year comorbidities    0.006
 0 (ref)    
 1 or more 1.33 (1.09–1.62)  
Surgery type    0.97
 Breast-conserving surgery (ref)    
 Mastectomy 1.00 (0.87–1.15)  
Endocrine therapy    0.003
 Tamoxifen only (ref)    
 AIs only 0.77 (0.64–0.92)  
 Tamoxifen and AIs 1.02 (0.85–1.24)  
Chemotherapy    0.31
 Yes 0.92 (0.78–1.08)  
 No (ref)    
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, AI aromatase inhibitor